P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In

News Categories

 

 

 

GSK to Reveal Drug Secrets

Company makes TB ‘compound library’ available to stimulate research (Oct. 11)

GlaxoSmithKline (GSK) announced on October 11 that it will establish new measures to help develop new and faster-acting treatments for tuberculosis (TB), a global health need where R&D has been at an impasse, and to support independent research into diseases of the developing world.

GSK will also outline new commitments to share detailed clinical trial data to enable additional scientific inquiry and analyses to further scientific knowledge and to help bring benefit to patients.

GSK scientists have screened the company’s entire pharmaceutical compound library of more than two million compounds for any that may inhibit TB bacteria and will publish the results of this process in a scientific journal — about 200 promising “hits” that could act as new starting points for the discovery of new medicines for TB.

This is the first time a pharmaceutical company will make public its own proprietary compounds that have demonstrated signs of activity against TB. GSK hopes this will encourage others to pursue an open approach to research into a disease that causes approximately 1.5 million deaths around the world every year.

This initiative builds on similar work carried out by GSK in 2009 to place all of its malaria compounds in the public domain. Since the publication of these data in 2010, GSK’s anti-malarial dataset has been shared with research institutions around the world, resulting in a number of promising research projects now under way.

GSK also announced that the company will create a system that will enable researchers to access the detailed patient-level data that support the results of clinical trials of its approved medicines and discontinued investigational medicines. To ensure that this information will be used for valid scientific purposes, researchers’ requests will be reviewed for scientific merit by an independent panel of experts, and, if approved, access will be granted via a secure web site. This will enable researchers to examine the data more closely or to combine data from different studies in order to conduct further research, to learn more about how medicines work in different patient populations, and to help optimize the use of medicines with the aim of improving patient care.

For more information, visit the GSK Web site.

More stories